Story · Medicine & Biotech

Thomas Hope: Combining Immunotherapy and PRRT to Improve Outcomes in High-Grade NETs

1 outlet · first reported by OncoDaily on

Thomas Hope, Professor in Residence at University of California, shared on LinkedIn: “Can immunotherapy improve PRRT in high-grade NETs? Nicholas Fidelman led our pilot study combining pembrolizumab with 177Lu-DOTATATE, which (OncoDaily)

Coverage, in order

  1. OncoDaily obscure study
    Thomas Hope: Combining Immunotherapy and PRRT to Improve Outcomes in High-Grade NETs

    Thomas Hope, Professor in Residence at University of California, shared on LinkedIn: “Can immunotherapy improve PRRT in high-grade NETs? Nicholas Fidelman led our pilot study combining pembrolizumab with 177Lu-DOTATATE, which

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.